Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sino Biopharmaceutical ( (HK:1177) ) just unveiled an announcement.
Sino Biopharmaceutical Limited announced that its Investigational New Drug application for TQB3142, a novel PROTAC molecule targeting Bcl-xL protein for the treatment of malignant tumors, has been accepted by China’s National Medical Products Administration. This innovative drug is designed to induce apoptosis in tumor cells with a reduced risk of platelet toxicity, offering a promising new treatment option in a field where no Bcl-xL inhibitors are currently approved worldwide.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$6.19 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a company in the pharmaceutical industry, focusing on the development of innovative drugs. It specializes in treatments for malignant tumors and operates with a market focus on China.
Average Trading Volume: 171,949,544
Technical Sentiment Signal: Buy
Current Market Cap: HK$132.9B
See more insights into 1177 stock on TipRanks’ Stock Analysis page.